The role of innate immunity receptors in the pathogenesis of inflammatory bowel disease

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Elia, Paula Peruzzi ^a   Tolentino, Yolanda Faia M ^a   Bernardazzi, Claudio ^a   De Souza, Heitor Siffert Pereira ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHEMOKINE; CRYOPYRIN; CYTOKINE; INFLAMMASOME; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR;

BACTERIAL CLEARANCE; CROHN DISEASE; DISEASE PREDISPOSITION; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRACT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIUM; LAMINA PROPRIA; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; EPITHELIUM; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; EPITHELIUM; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84925307988     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/936193     Document Type: Review

References (103)

1. Human Microbiome Project Consortium, "Structure, function and diversity of the healthy human microbiome," Nature, vol. 486, no. 7402, pp. 207-214, 2012.
2. L. V. Hooper and A. J. MacPherson, "Immune adaptations that maintain homeostasis with the intestinal microbiota," Nature Reviews Immunology, vol. 10, no. 3, pp. 159-169, 2010.
3. R. E. Ley, D. A. Peterson, and J. I. Gordon, "Ecological and evolutionary forces shaping microbial diversity in the human intestine," Cell, vol. 124, no. 4, pp. 837-848, 2006.
4. M. Hattori and T.D. Taylor, "The human intestinal microbiome: a new frontier of human biology," DNA Research, vol. 16, no. 1, pp. 1-12, 2009.
5. D. A. Hill and D. Artis, "Intestinal bacteria and the regulationof immune cell homeostasis," Annual Review of Immunology, vol. 28, pp. 623-667, 2010.
6. A. L. Hart and P. Hendy, "The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre," The Proceedings of the Nutrition Society, vol. 73, no. 4, pp. 452-456, 2014.
7. D. Knights, K. G. Lassen, and R. J. Xavier, "Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome," Gut, vol. 62, no. 10, pp. 1505-1510, 2013.
8. M. Z. Cader and A. Kaser, "Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation," Gut, vol. 62, no. 11, pp. 1653-1664, 2013.
9. R. Medzhitov and C. Janeway Jr., "Innate immunity," The New England Journal of Medicine, vol. 343, no. 5, pp. 338-344, 2000.
10. A. Iwasaki and R. Medzhitov, "Toll-like receptor control of the adaptive immune responses," Nature Immunology, vol. 5, no. 10, pp. 987-995, 2004.
11. S. Akira, S. Uematsu, and O. Takeuchi, "Pathogen recognition and innate immunity," Cell, vol. 124, no. 4, pp. 783-801, 2006.
12. P. J. Sansonetti, "Theinnate signaling of dangers and the dangers of innate signaling," Nature Immunology, vol. 7, no. 12, pp. 1237-1242, 2006.
13. C. A. Janeway Jr. and R. Medzhitov, "Innate immune recognition," Annual Review of Immunology, vol. 20, pp. 197-216, 2002.
14. J. M. Wells, O. Rossia, M. Meijerink, and P. Van Baarlen, "Epithelial crosstalk at the microbiota-mucosal interface," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 1, pp. 4607-4614, 2011.
15. S. Akira and K. Takeda, "Toll-like receptor signalling," Nature Reviews Immunology, vol. 4, no. 7, pp. 499-511, 2004.
16. M.W. Hornef, B. H. Normark, A. Vandewalle, and S. Normark, "Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells," The Journal of Experimental Medicine, vol. 198, no. 8, pp. 1225-1235, 2003.
17. M. T. Abreu, "Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function," Nature Reviews Immunology, vol. 10, no. 2, pp. 131-143, 2010.
18. J. M. Wells, L. M. P. Loonen, and J. M. Karczewski, "The role of innate signaling in the homeostasis of tolerance and immunity in the intestine," International Journal of Medical Microbiology, vol. 300, no. 1, pp. 41-48, 2010.
19. E. Cario, I. M. Rosenberg, S. L. Brandwein, P. L. Beck, H.-C. Reinecker, and D. K. Podolsky, "Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors," The Journal of Immunology, vol. 164, no. 2, pp. 966-972, 2000.
20. J. Lee, J.-H. Mo, K. Katakura et al., "Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells," Nature Cell Biology, vol. 8, no. 12, pp. 1327-1336, 2006.
21. A. Williams, R. A. Flavell, and S. C. Eisenbarth, "The role of NOD-like receptors in shaping adaptive immunity," Current Opinion in Immunology, vol. 22, no. 1, pp. 34-40, 2010.
22. J. P.-Y. Ting, D. L. Kastner, and H. M. Hoffman, "CATERPILLERs, pyrin and hereditary immunological disorders," Nature Reviews Immunology, vol. 6, no. 3, pp. 183-195, 2006.
23. M. Chamaillard, M. Hashimoto, Y. Horie et al., "An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid," Nature Immunology, vol. 4, no. 7, pp. 702-707, 2003.
24. S. E. Girardin, I. G. Boneca, L. A. M. Carneiro et al., "Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan," Science, vol. 300, no. 5625, pp. 1584-1587, 2003.
25. M. Hasegawa, K. Yang, M. Hashimoto et al., "Differential release and distribution of Nod1 and Nod2 immunostimulatory molecules among bacterial species and environments," The Journal of Biological Chemistry, vol. 281, no. 39, pp. 29054-29063, 2006.
26. D. Bouskra, C. Brézillon, M. Bérard et al., "Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis," Nature, vol. 456, no. 7221, pp. 507-510, 2008.
27. N. Inohara, T. Koseki, L. del Peso et al., "Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB," Journal of Biological Chemistry, vol. 274, no. 21, pp. 14560-14567, 1999.
28. J. G. Kim, S. J. Lee, and M. F. Kagnoff, "Nod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors," Infection and Immunity, vol. 72, no. 3, pp. 1487-1495, 2004.
29. S. Lala, Y. Ogura, C. Osborne et al., "Crohn's disease and the NOD2 gene: a role for paneth cells," Gastroenterology, vol. 125, no. 1, pp. 47-57, 2003.
30. P. Rosenstiel and S. Sebreiber, "NOD-like receptors-pivotal guardians of the immunological integrity of barrier organs," Advances in Experimental Medicine and Biology, vol. 653, pp. 35-47, 2009.
31. K. S. Kobayashi, M. Chamaillard, Y. Ogura et al., "Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract," Science, vol. 307, no. 5710, pp. 731-734, 2005.
32. P. K. Boughan, R. H. Argent, M. Body-Malapel et al., "Nucleotide-binding oligomerization domain-1 and epidermal growth factor receptor: critical regulators of β-defensins during Helicobacter pylori infection," The Journal of Biological Chemistry, vol. 281, no. 17, pp. 11637-11648, 2006.
33. F. Martinon, K. Burns, and J. Tschopp, "The Inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta," Molecular Cell, vol. 10, no. 2, pp. 417-426, 2002.
34. S. Mariathasan, D. S. Weiss, K. Newton et al., "Cryopyrin activates the inflammasome in response to toxins and ATP," Nature, vol. 440, no. 7081, pp. 228-232, 2006.
35. L. Agostini, F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp, "NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder," Immunity, vol. 20, no. 3, pp. 319-325, 2004.
36. T. D. Kanneganti, M. Lamkanfi, Y.-G. Kim et al., "Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling," Immunity, vol. 26, no. 4, pp. 433-443, 2007.
37. T.-D. Kanneganti, M. Lamkanfi, and G. Núñez, "Intracellular NOD-like receptors in host defense and disease," Immunity, vol. 27, no. 4, pp. 549-559, 2007.
38. B. Faustin, L. Lartigue, J.-M. Bruey et al., "Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation," Molecular Cell, vol. 25, no. 5, pp. 713-724, 2007.
39. F. Martinon, L. Agostini, E. Meylan, and J. Tschopp, "Identification of bacterial muramyl dipeptide as activator of the NALP3/Cryopyrin inflammasome," Current Biology, vol. 14, no. 21, pp. 1929-1934, 2004.
40. T. D. Kanneganti, M. Body-Malapel, A. Amer et al., "Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA," The Journal of Biological Chemistry, vol. 281, no. 48, pp. 36560-36568, 2006.
41. D. A. Muruve, V. Pétrilli, A. K. Zaiss et al., "The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response," Nature, vol. 452, no. 7183, pp. 103-107, 2008.
42. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, "Gout-associated uric acid crystals activate the NALP3 inflammasome," Nature, vol. 440, no. 7081, pp. 237-241, 2006.
43. S. F. Murphy, J. H. Kwon, and D. L. Boone, "Novel players in inflammatory bowel disease pathogenesis," Current Gastroenterology Reports, vol. 14, no. 2, pp. 146-152, 2012.
44. E. Furrie, S. Macfarlane, G. Thomson, and G. T. Macfarlane, "Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria," Immunology, vol. 115, no. 4, pp. 565-574, 2005.
45. M. Fukata, A. Chen, A. S. Vamadevan et al., "Toll-like receptor- 4 promotes the development of colitis-associated colorectal tumors," Gastroenterology, vol. 133, no. 6, pp. 1869.e2-1881.e2, 2007.
46. E. Cario and D. K. Podolsky, "Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease," Infection and Immunity, vol. 68, no. 12, pp. 7010-7017, 2000.
47. M. Hausmann, S. Kiessling, S. Mestermann et al., "Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation," Gastroenterology, vol. 122, no. 7, pp. 1987-2000, 2002.
48. M. Brown, K. R. Hughes, S. Moossavi, A. Robins, and Y. R. Mahida, "Toll-like receptor expression in crypt epithelial cells, putative stem cells and intestinal myofibroblasts isolated from controls and patients with inflammatory bowel disease," Clinical & Experimental Immunology, vol. 178, no. 1, pp. 28-39, 2014.
49. A. S. Neish, "Microbes in gastrointestinal health and disease," Gastroenterology, vol. 136, no. 1, pp. 65-80, 2009.
50. A. T. Gewirtz, "Flag in the crossroads: flagellinmodulates innate and adaptive immunity," Current Opinion in Gastroenterology, vol. 22, no. 1, pp. 8-12, 2006.
51. H. Zeng, A. Q. Carlson, Y. Guo et al., "Flagellin is the major proinflammatory determinant of enteropathogenic Salmonella," The Journal of Immunology, vol. 171, no. 7, pp. 3668-3674, 2003.
52. M. Vijay-Kumar, H. Wu, R. Jones et al., "Flagellin suppresses epithelial apoptosis and limits disease during enteric infection," The American Journal of Pathology, vol. 169, no. 5, pp. 1686-1700, 2006.
53. H. Zeng, H. Wu, V. Sloane et al., "Flagellin/TLR5 responses in epithelia reveal intertwined activation of inflammatory and apoptotic pathways," American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 1, pp. G96-G108, 2006.
54. M. Vijay-Kumar, C. J. Sanders, R. T. Taylor et al., "Deletion of TLR5 results in spontaneous colitis in mice," The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3909-3921, 2007.
55. A. Franke, D. P. McGovern, and J. C. Barrett, "Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci," Nature Genetics, vol. 42, no. 12, pp. 1118-1125, 2010.
56. C. A. Anderson, G. Boucher, C. W. Lees et al., "Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47," Nature Genetics, vol. 43, no. 3, pp. 246-252, 2011.
57. G. Gibson, "Hints of hidden heritability in GWAS," Nature Genetics, vol. 42, no. 7, pp. 558-560, 2010.
58. N. A. Molodecky, I. S. Soon, D. M. Rabi et al., "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review," Gastroenterology, vol. 142, no. 1, pp. 46.e42-54.e42, 2012.
59. S. Uematsu and K. Fujimoto, "The innate immune system in the intestine," Microbiology and Immunology, vol. 54, no. 11, pp. 645-657, 2010.
60. J.-P. Hugot, M. Chamaillard, H. Zouali et al., "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease," Nature, vol. 411, no. 6837, pp. 599-603, 2001.
61. Y. Ogura, D. K. Bonen, N. Inohara et al., "A frameshiftmutation in NOD2 associated with susceptibility to Crohn's disease," Nature, vol. 411, no. 6837, pp. 603-606, 2001.
62. W. Strober and T. Watanabe, "NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease," Mucosal Immunology, vol. 4, no. 5, pp. 484-495, 2011.
63. D. Corridoni, K. O. Arseneau, M. G. Cifone, and F. Cominelli, "The dual role of nod-like receptors in mucosal innate immunity and chronic intestinal inflammation," Frontiers in Immunology, vol. 5, p. 317, 2014.
64. Y. Ogura, N. Inohara, A. Benito, F. F. Chen, S. Yamaoka, and G. Núñez, "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB," The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4812-4818, 2001.
65. D. J. Philpott, M. T. Sorbara, S. J. Robertson, K. Croitoru, and S. E. Girardin, "NOD proteins: regulators of inflammation in health and disease," Nature Reviews Immunology, vol. 14, no. 1, pp. 9-23, 2014.
66. R. Cooney, J. Baker, O. Brain et al., "NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation," Nature Medicine, vol. 16, no. 1, pp. 90-97, 2010.
67. C. S. Wagner and P. Cresswell, "TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation," The Journal of Immunology, vol. 188, no. 2, pp. 686-693, 2012.
68. O. Gutierrez, C. Pipaon, N. Inohara et al., "Induction of Nod2 inmyelomonocytic and intestinal epithelial cells vianuclear factor-kappaB activation," The Journal of Biological Chemistry, vol. 277, no. 44, pp. 41701-41705, 2002.
69. J. T. Tigno-Aranjuez and D. W. Abbott, "Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1823, no. 11, pp. 2022-2028, 2012.
70. A. Negroni, L. Stronati, M. Pierdomenico et al., "Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohn's disease," Inflammatory Bowel Diseases, vol. 15, no. 8, pp. 1145-1154, 2009.
71. J. Jamontt, S. Petit, N. Clark, S. J. Parkinson, and P. Smith, "Nucleotide-binding oligomerization domain 2 signaling promotes hyperresponsive macrophages and colitis in IL-10-deficient mice," Journal of Immunology, vol. 190, no. 6, pp. 2948-2958, 2013.
72. T. Watanabe, A. Kitani, P. J. Murray, and W. Strober, "NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses," Nature Immunology, vol. 5, no. 8, pp. 800-808, 2004.
73. E. Cantó, E. Moga, E. Ricart et al., "MDP-induced selective tolerance to TLR4 ligands: impairment in NOD2 mutant Crohn's disease patients," Inflammatory Bowel Diseases, vol. 15, no. 11, pp. 1686-1696, 2009.
74. B. Levine, N. Mizushima, and H. W. Virgin, "Autophagy in immunity and inflammation," Nature, vol. 469, no. 7330, pp. 323-335, 2011.
75. J. Hampe, A. Franke, P. Rosenstiel et al., "A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1," Nature Genetics, vol. 39, no. 2, pp. 207-211, 2007.
76. J.D. Rioux, R. J. Xavier, K. D. Taylor et al., "Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis," Nature Genetics, vol. 39, no. 5, pp. 596-604, 2007.
77. C. R. Homer, A. L. Richmond, N. A. Rebert, J. Achkar, and C. McDonald, "ATG16L1 and NOD2 interact in an autophagydependent antibacterial pathway implicated in Crohn's disease pathogenesis," Gastroenterology, vol. 139, no. 5, pp. 1630.e2-1641.e2, 2010.
78. T. B. Clarke, K. M. Davis, E. S. Lysenko, A. Y. Zhou, Y. Yu, and J. N. Weiser, "Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity," Nature Medicine, vol. 16, no. 2, pp. 228-231, 2010.
79. D. P. B. McGovern, P. Hysi, T. Ahmad et al., "Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease," Human Molecular Genetics, vol. 14, no. 10, pp. 1245-1250, 2005.
80. G.Y. Chen, M.H. Shaw, G. Redondo, and G. Núñez, "The Innate immune receptor nod1 protects the intestine from inflammation-induced tumorigenesis," Cancer Research, vol. 68, no. 24, pp. 10060-10067, 2008.
81. A.-C. Villani, M. Lemire, G. Fortin et al., "Common variants in the NLRP3 region contribute to Crohn's disease susceptibility," Nature Genetics, vol. 41, no. 1, pp. 71-76, 2009.
82. I. Schoultz, D. Verma, J. Halfvarsson et al., "Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to crohn's disease in swedish men," The American Journal of Gastroenterology, vol. 104, no. 5, pp. 1180-1188, 2009.
83. G. J. Lewis, D. C.O. Massey, H. Zhang et al., "Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel," Inflammatory Bowel Diseases, vol. 17, no. 6, pp. 1387-1391, 2011.
84. K. Tamura, Y. Fukuda, H. Sashio et al., "IL18 polymorphism is associated with an increased risk of crohn's disease," Journal of Gastroenterology, vol. 37, supplement 14, pp. 111-116, 2002.
85. G. Monteleone, F. Trapasso, T. Parrello et al., "Bioactive IL-18 expression is up-regulated in Crohn's disease," The Journal of Immunology, vol. 163, no. 1, pp. 143-147, 1999.
86. K. A. Papadakis and S. R. Targan, "Role of cytokines in the pathogenesis of inflammatory bowel disease," Annual Review of Medicine, vol. 51, pp. 289-298, 2000.
87. 7 receptor," The EMBO Journal, vol. 25, no. 21, pp. 5071-5082, 2006.
88. N. E. de Campos, C. Marques-da-Silva, G. Corrêa, M. T. L. Castelo-Branco, H. S. P. de Souza, and R. Coutinho-Silva, "Characterizing the presence and sensitivity of the P2X7 receptor in different compartments of the gut," Journal of Innate Immunity, vol. 4, no. 5-6, pp. 529-541, 2012.
89. L. Welter-Stahl, C.M. da Silva, J. Schachter et al., "Expression of purinergic receptors and modulation of P2X7 function by the inflammatory cytokine IFNγ in human epithelial cells," Biochimica et Biophysica Acta-Biomembranes, vol. 1788, no. 5, pp. 1176-1187, 2009.
90. C. O. Souza, G. F. Santoro, V. R. Figliuolo et al., "Extracellular ATP induces cell death in human intestinal epithelial cells," Biochimica et Biophysica Acta, vol. 1820, no. 12, pp. 1867-1878, 2012.
91. F. A. Carvalho, I. Nalbantoglu, J. D. Aitken et al., "Cytosolic flagellin receptor NLRC4 protects mice againstmucosal and systemic challenges," Mucosal Immunology, vol. 5, no. 3, pp. 288-298, 2012.
92. E. A. Miao, I. A. Leaf, P. M. Treuting et al., "Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria," Nature Immunology, vol. 11, no. 12, pp. 1136-1142, 2010.
93. M. S. F. Pereira, G. F. Morgantetti, L.M. Massis, C. V. Horta, J. I. Hori, and D. S. Zamboni, "Activation of NLRC4 by flagellated bacteria triggers caspase-1-dependent and -independent responses to restrict Legionella pneumophila replication in macrophages and in vivo," The Journal of Immunology, vol. 187, no. 12, pp. 6447-6455, 2011.
94. J. von Moltke, J. S. Ayres, E. M. Kofoed, J. Chavarría-Smith, and R. E. Vance, "Recognition of bacteria by inflammasomes," Annual Review of Immunology, vol. 31, pp. 73-106, 2013.
95. J. Tomalka, S. Ganesan, E. Azodi et al., "A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen Candida albicans," PLoS Pathogens, vol. 7, no. 12, Article ID e1002379, 2011.
96. T.E. West, N. D. Myers, N. Chantratita et al., "NLRC4 and TLR5 each contribute to host defense in respiratory melioidosis," PLoS Neglected Tropical Diseases, vol. 8, no. 9, Article ID e3178, 2014.
97. D. S. Zamboni, K. S. Kobayashi, T. Kohlsdorf et al., "The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection," Nature Immunology, vol. 7, no. 3, pp. 318-325, 2006.
98. D. S. Zamboni and L. D. Cunha, "Subversion of inflammasome activation and pyroptosis by pathogenic bacteria," Frontiers in Cellular and Infection Microbiology, vol. 4, article 76, 2013.
99. G. Y. Chen, M. Liu, F. Wang, J. Bertin, and G. Núñez, "A functional role for Nlrp6 in intestinal inflammation and tumorigenesis," The Journal of Immunology, vol. 186, no. 12, pp. 7187-7194, 2011.
100. E. Elinav, T. Strowig, A. L. Kau et al., "NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis," Cell, vol. 145, no. 5, pp. 745-757, 2011.
101. S. Normand, A. Delanoye-Crespin, A. Bressenot et al., "Nodlike receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 23, pp. 9601-9606, 2011.
102. M. H. Zaki, P. Vogel, R. K. S. Malireddi et al., "The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis," Cancer Cell, vol. 20, no. 5, pp. 649-660, 2011.
103. I. C. Allen, J. E. Wilson, M. Schneider et al., "NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF- κB signaling," Immunity, vol. 36, no. 5, pp. 742-754, 2012.